150 related articles for article (PubMed ID: 25059880)
1. Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis?
Erre GL; Pardini S; Cuccuru L; Taras L; Passiu G
Joint Bone Spine; 2015 Jan; 82(1):72-3. PubMed ID: 25059880
[No Abstract] [Full Text] [Related]
2. Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase?
Josselin-Mahr L; Werbrouck-Chiraux A; Garderet L; Cabane J
Rheumatology (Oxford); 2014 Feb; 53(2):378-9. PubMed ID: 23893665
[No Abstract] [Full Text] [Related]
3. Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report.
Beketova TV; Volkov MY; Naryshkin EA; Novoselova TM; Nasonov EL
Clin Rheumatol; 2018 Jun; 37(6):1729-1735. PubMed ID: 29564565
[TBL] [Abstract][Full Text] [Related]
4. 3. Imatinib therapy in chronic myelogenous leukemia.
Jinnai I
Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
[No Abstract] [Full Text] [Related]
5. Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia.
Mughal TI; Goldman JM
Clin Med (Lond); 2006; 6(6):526-8. PubMed ID: 17228548
[No Abstract] [Full Text] [Related]
6. Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
Mauro MJ
Curr Treat Options Oncol; 2007 Aug; 8(4):287-95. PubMed ID: 18157514
[No Abstract] [Full Text] [Related]
7. [Updates on pathology of soft tissue tumors].
Yu L; Wang J
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):145-6. PubMed ID: 23769430
[No Abstract] [Full Text] [Related]
8. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
9. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for imatinib in inflammatory bowel disease?
De Backer O; Lefebvre RA
Inflamm Bowel Dis; 2008 Apr; 14(4):579-81. PubMed ID: 18050299
[No Abstract] [Full Text] [Related]
11. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease.
Stadler M; Ahlborn R; Kamal H; Diedrich H; Buchholz S; Eder M; Ganser A
Blood; 2009 Oct; 114(17):3718-9; author reply 3719-20. PubMed ID: 19850751
[No Abstract] [Full Text] [Related]
12. Hits and misses in targeting pediatric cancers.
Bernstein ML
Pediatr Blood Cancer; 2009 Jul; 52(7):751-2. PubMed ID: 19185009
[No Abstract] [Full Text] [Related]
13. Imatinib mesylate induces clinical remission in rheumatoid arthritis.
Pereira I; Fialho S; Castro G; Zimmermann A
Joint Bone Spine; 2010 Jul; 77(4):372-3. PubMed ID: 20478730
[No Abstract] [Full Text] [Related]
14. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-KrzemieĊ S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
15. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
16. Long-term imatinib maintenance therapy for adult Philadelphia positive acute lymphoblastic leukemia.
Guillet S; Hirsch P; Marzac C; Mohty M; Marie JP; Legrand O
Leuk Lymphoma; 2014 Nov; 55(11):2646-8. PubMed ID: 24491028
[No Abstract] [Full Text] [Related]
17. Novel approaches to therapy of hypereosinophilic syndromes.
Simon HU; Cools J
Immunol Allergy Clin North Am; 2007 Aug; 27(3):519-27. PubMed ID: 17868862
[TBL] [Abstract][Full Text] [Related]
18. Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes.
Little PJ; Cohen N; Morahan G
ScientificWorldJournal; 2009 Mar; 9():224-8. PubMed ID: 19347233
[No Abstract] [Full Text] [Related]
19. Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors.
Siegel A
Gastroenterology; 2008 Sep; 135(3):733-5. PubMed ID: 18692053
[No Abstract] [Full Text] [Related]
20. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
[No Abstract] [Full Text] [Related]
[Next] [New Search]
